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Snakebite is a priority neglected tropical disease and causes a range of complications that
vary depending on the snake species. Randomised clinical trials have used varied outcome
measures that do not allow results to be compared or combined. In accordance with the
Core Outcomes Measurements in Effectiveness Trials (COMET) initiative, this systematic
review aims to support the development of a globally relevant core outcome set for
snakebite.
Methods
All randomised controlled trials, secondary analyses of randomised controlled trials and
study protocols investigating the efficacy of therapeutics for human snakebite envenoming
were eligible for inclusion. Study screening and data extraction were conducted in duplicate
by two independent reviewers. All primary and secondary outcome measures were
extracted and compiled, as were adverse event outcome measures. Similar outcome mea-
sures were grouped into domains. The study was prospectively registered with PROS-
PERO: CRD42020196160.
Results
This systematic review included 43 randomised controlled trials, two secondary analyses
and 13 study protocols. A total of 382 outcome measures were extracted and, after dupli-
cates were merged, there were 153 unique outcomes. The most frequently used outcome
domain (‘venom antigenaemia’) was included in less than one third of the studies. The
unique outcomes were classified into 60 outcome domains. Patient-centred outcomes were
used in only three of the studies.







Citation: Abouyannis M, Aggarwal D, Lalloo DG,
Casewell NR, Hamaluba M, Esmail H (2021)
Clinical outcomes and outcome measurement
tools reported in randomised controlled trials of
treatment for snakebite envenoming: A systematic
review. PLoS Negl Trop Dis 15(8): e0009589.
https://doi.org/10.1371/journal.pntd.0009589
Editor: Abdulrazaq G. Habib, College of Health
Sciences, Bayero University Kano, NIGERIA
Received: February 10, 2021
Accepted: June 24, 2021
Published: August 2, 2021
Peer Review History: PLOS recognizes the
benefits of transparency in the peer review
process; therefore, we enable the publication of
all of the content of peer review and author
responses alongside final, published articles. The
editorial history of this article is available here:
https://doi.org/10.1371/journal.pntd.0009589
Copyright: © 2021 Abouyannis et al. This is an
open access article distributed under the terms of
the Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
Information files.
Discussion
Significant heterogeneity in outcome measures exists in snakebite clinical trials. Consensus
is needed to select outcome measures that are valid, reliable, patient-centred and feasible.
The results of this systematic review strongly support the development of a core outcome
set for use in snakebite clinical trials.
Author summary
Standardised outcome measures for snakebite randomised controlled trials are needed to
enable results to be compared and combined between studies. This systematic review was
conducted to understand the variations in outcome measure use in snakebite randomised
controlled trials, and to create a comprehensive list of outcome measures from which to
develop a core outcome set (COS). A total of 153 unique outcome measures were
extracted from the 58 studies identified in this systematic review. Of these 153 unique out-
come measures, 91 were used in only in a single study. Although a form of bedside whole
blood clotting test was used in 30 of the 58 studies, 18 unique methods of measurement
were identified. Only three studies, all conducted in the USA, included patient-centred
outcomes. This systematic review demonstrates the strong need for a snakebite core out-
come set, which will support the adoption of valid, reproducible, and patient-centred out-
come measures, and enable downstream meta-analyses.
Introduction
Global estimates indicate that there are 1�8 million envenomings and 94,000 deaths each year
due to snakebite, with the highest burden in sub-Saharan Africa and Asia [1].
There is significant within-species and between-species variability in the toxins found in
snake venoms [2], which account for the broad range of clinical manifestations caused by
envenoming [3]. Syndromes of systemic envenoming include neurotoxicity, haemorrhage,
and coagulopathy. Local effects can range from swelling to tissue necrosis, and are an impor-
tant cause of disability and limb amputation [4]. Other effects of envenoming include myotoxi-
city, hypotension, and renal injury.
There has been limited funding for snakebite research, with a global average of under 5 mil-
lion USD invested per annum [5], and a resulting paucity of clinical trials [6]. Antivenom is
the only specific therapy for treating the aetiological toxins injected during snakebite, yet their
use is rarely supported by clinical efficacy data or a rigorous regulatory framework [7]. How-
ever, in 2017 the World Health Organization reinstated snakebite envenoming as a category A
neglected tropical disease [8], and thus funding to support snakebite management is antici-
pated to increase. Appropriate outcome measures are vital for ensuring that findings are rele-
vant to patients and can appropriately inform policy makers. They need to be valid and
reliable, particularly when surrogate endpoints are relied upon.
The Core Outcome Measures in Effectiveness Trials (COMET) Initiative has advocated for
and supported the development of core outcome sets (COS) in clinical research [9]. These are
developed by collaborative groups of researchers, clinicians, and patients; to identify an agreed
minimum set of outcome measures for a disease area. By using a core outcome set, it is easier
to compare, contrast and combine results of clinical trials, which has rarely been possible in
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the field of snakebite [10,11]. The first step toward developing a COS is to undertake a system-
atic review of the existing literature to inform. This systematic review aims to describe the het-
erogeneity in outcome measures used across clinical trials and will provide a comprehensive
resource of outcome measures that can be considered when developing a COS.
Methods
Search strategy and selection criteria
Databases were searched for randomised controlled trials and trial protocols wherein thera-
peutics that inhibit venom, or its downstream pathological effects, were studied. MEDLINE,
Cochrane CENTRAL, Web of Science and Embase were searched from database inception
until the 23rd of June 2020, with no language restriction, using the search terms ([“Snake bite”
OR “snake envenomation” OR “snake venoms” OR “antivenoms” OR “antivenins] and [“ran-
domised controlled trial” OR “randomised” OR “randomized” OR “randomly” OR “placebo”
OR “double-blind” OR “single-blind” OR “clinical trial”]. Reference lists of included studies
were searched. The following trial registries were searched: Australian trial register; Interna-
tional Standard Randomised Controlled Trial register; Clinical Trials Registry India; Chinese
clinical trials registry; Clinical trial gov; Sri Lanka Clinical Trials Registry; Japan Primary Reg-
istries Network; WHO ICTRP. Full details of the search strategy were uploaded to PROSPERO
(CRD42020196160).
Covidence systematic review software was used to compile, deduplicate and screen studies.
Two reviewers (MA and DA) independently screened titles and abstracts, and subsequently
the full-text articles. Full texts were translated to English language when necessary. Disagree-
ments were resolved by consensus discussion with a third reviewer (HE). All reviewers (MA,
DA and HE) are clinical academics with experience of interpreting clinical trials. Studies of
adjunctive therapies that proposed to treat either antivenom hypersensitivity reactions or bite-
site infection were excluded. Published secondary analyses of randomised controlled trials
were included if they provided additional outcome measures.
Data extraction
Prespecified data (as reported in S1 Text) were independently extracted and standardised by
two authors (MA and DA). All primary, secondary, and adverse event outcome measures were
extracted verbatim from full-text articles and study protocols. Outcome measures were
grouped into the following predefined categories: haemorrhage; coagulopathy; neurotoxicity;
local tissue damage; renal injury; cardiotoxicity; myotoxicity; mortality; venom antigenaemia;
additional antivenom requirement; functional status; scoring system; composite outcome; or
other.
Data synthesis
After merging duplicate outcome measures, a data driven approach was used to classify them
into domains. Each domain represented a grouping of outcomes that were deemed to be mea-
suring a similar parameter. Consensus on domain allocations and domain names was reached
by the primary authors. The characteristics of the studies and the outcome measures were
summarised using descriptive statistics. The methodological quality of the primary and sec-
ondary outcome measures was assessed by the independent reviewers (MA and DA) using an
established tool (as reported in S2 Text) [12]. The reviewers assessed whether each outcome
measure was clearly stated; clearly defined; and patient-centred.
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The database searches identified 2,421 studies, of which 687 were duplicates (Fig 1). Review of
titles and abstracts identified 79 potentially eligible studies. All full texts were obtained and two
required translation to English language. Searching of clinical trial registries identified two fur-
ther protocols. Following full text review, 43 randomised controlled trials, 13 trial protocols
and two published secondary analyses were included. Amongst the 13 included protocols, 6
had been terminated and 7 were ongoing. Two published secondary analyses [13,14] utilised
data from the clinical trial published by Gerardo et al [15] and reported the additional outcome
measures ‘opiate use’ and ‘the physical function domain of the SF-36 questionnaire’. Table 1
details the characteristics of all the included studies.
Characteristics of included randomised controlled trials
The proportion of randomised controlled trials conducted in each region were: Asia, 51�2%
(n = 22 of 43); South America, 25�6% (n = 11); North America, 9�3% (n = 4); Africa, 9�3%
(n = 4) (all in Nigeria); and Australasia, 4�7% (2) (Fig 2). The proportion published per decade
were: 1960–69, 2�3% (n = 1 of 43); 1970–79, 2�3% (n = 1); 1980–89, 14�0% (n = 6); 1990–99,
27�9% (n = 12); 2000–09, 25�6% (n = 11); 2010–19, 25�6% (n = 11); and 2020, 2�3% (n = 1).
Across the 43 trials, 3,418 participants were randomised. The mean sample size was 79 (IQR
41–100) and in 74�4% (n = 32 of 43) of studies the sample size was�100. The majority (55�8%;
n = 24 of 43) were single centre studies, and the four trials with the greatest number of recruit-
ment sites (range 7–28 sites) were conducted exclusively in Australia or the USA. Double
blinding was adopted in 44�1% (n = 19 of 43); single blinding in 4�7% (n = 2); and 51�1%
(n = 22) were open label. No pre-specified time-period of follow-up was defined in 55�8%
(n = 24) trials. Among those where a follow-up period was reported (n = 19), 89.5% (n = 17)
were for a period of 28 days or less; 5�3% (n = 1) were for 3-months; and 5�3% (n = 1) were for
6-months. Amongst trials published since January 2000 (N = 23), 43�5% (n = 10) reported a
sample size calculation; 65�2% (n = 15) reported the numbers of participants screened for eligi-
bility; and 43�5% (n = 10) were registered with a protocol available.
In 74�4% (n = 32 of 43) of randomised controlled trials, a method of identifying the biting
snake, to species, genus or sub-family taxonomic rank, was used. The majority of trials com-
bined two or more methods for identifying the snake. In 55�8% (n = 24) of clinical trials, the
morphology of the dead snake was opportunistically assessed (when the specimen was brought
into hospital), although other less specific methods of identification were often relied upon in
these trials, such as an assessment of the clinical syndrome of envenoming. The clinical syn-
drome of envenoming (together with valid assumptions of locally prevalent snake species) was
used to predict the biting species in 37�2% (n = 16) of clinical trials. Enzyme immunoassay, the
participant’s description of the snake’s appearance, or a photograph of the biting snake (taken
by the participant or a bystander) were assessed in 32�6% (n = 14), 18�6% (n = 8) and 4�7%
(n = 2) of clinical trials, respectively. The UpSet plot (Fig 3) demonstrates the size of intersec-
tions between the different methods of snake identification used across the 43 included clinical
trials. Amongst trials which identified the biting snake (n = 32), these were Viperidae in 87�5%
(n = 28) of studies, and Elapidae in 12�5% (n = 4) of studies. The most commonly studied
snake genera were Bothrops (34�4%; n = 11), Daboia (15�6%; n = 5) and Echis (12�1%; n = 4).
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Fig 1. Study selection strategy. RCT = randomised controlled trial.
https://doi.org/10.1371/journal.pntd.0009589.g001
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Participants with coagulopathy or haemorrhagic envenoming were studied in 81�4% of tri-
als (n = 35 of 43); local tissue damage in 69�8% (n = 30); renal injury in 25�6% (n = 11); neuro-
toxicity in 20�9% (n = 9); and myotoxicity in 2�3% (n = 1). Different antivenom products were
compared in 44�2% (n = 19) of trials; different doses of the same antivenom product were com-
pared in 23�3% (n = 10) of trials. Antivenom was compared to placebo in 9�3% (n = 4) of trials;
in all of these, participants with severe envenoming were excluded [15,16] or the biting species
was known to be associated with limited clinical manifestations [17,18]. Other therapies that
were compared were: heparin, 9�3% (n = 4) [19–22]; fresh frozen plasma, 4�7% (n = 2) [23,24];
atropine and edrophonium, 2�3% (n = 1) [25]; edrophonium and amifampridine, 2�3% (n = 1)
[26]; intravenous immunoglobulin, 2�3% (n = 1) [27]; and ‘Qingwen Baidu Decoction’ (a tra-
ditional Chinese medicine), 2�3% (n = 1) [28].
Quality of outcome measures
Amongst the trials and protocols (n = 56), 50�0% (n = 28) had a clearly stated primary out-
come. Amongst studies published since January 2000 (n = 36), 69�4% (n = 25) had a clearly
stated primary outcome. 80�0% (n = 20) of primary outcomes were clearly defined; 64%
(n = 16) were clinical endpoints and 36% (n = 9) were laboratory markers; and 4�0% (n = 1)
were patient centred. Across the secondary outcome measures from studies published since
January 2000 (n = 226), 64�6% (n = 146) were clearly defined; 56.6% (n = 128) were clinical
endpoints, 38.9% (n = 88) were laboratory markers, and 4.4% (n = 10) were exploratory; and
4�9% (n = 11) were patient centred.
Outcome measures
Across the 58 included studies, 382 outcome measures were extracted verbatim and, after
duplicates were merged, 153 unique outcomes were identified. 59�5% of unique outcome mea-
sures were unique to a single study; 18�3% were used in two studies; 5�9%, in three studies;
Fig 2. Total number of randomised controlled trial participants by country. The area of each circle is proportionate to the total
number of trial participants randomised per country in studies published between 1946 and 2020. The area of the segments of each
circle are proportionate to the sample size of individual RCTs (e.g., there has been one large trial and three small trials conducted in
Nigeria). Each circle overlies the country that it refers to. Where circles would overlap they have been moved, and the edge of the circle
touches the corresponding country. The key demonstrates the samples size that corresponds to the surface area of two example circles.
World map sourced from the Natural Earth project (1:50m resolution version) https://www.naturalearthdata.com.
https://doi.org/10.1371/journal.pntd.0009589.g002
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4�6%, in four studies; and 11�8% were used in five or more studies. There was no single out-
come that was used across all the studies, and the most frequently used outcome domain
(‘venom antigenaemia’) was included in 32�8% of studies (n = 19 of 58). Venom antigenaemia
was measured using various assays; the majority of which are not commercially available.
39�8% of the 382 extracted outcome measures did not report a specific timing of measurement.
Amongst those with a time-point, 35�7% were measured for less than 24 hours; 42�6%, for less
than a week; 16�5%, for less than a month; and 5�2% for up to 6-months. A summary of the
durations of follow-up of outcome measures, grouped by category of envenoming, are pre-
sented in Fig 4. Full extracted outcome measure data is available in (S1 Data).
The 28 primary outcome measures were categorised as follows: composite outcome, 8; coa-
gulopathy, 6; neurotoxicity, 4; local tissue damage, 2; additional antivenom requirement, 1;
functional status, 1; myotoxicity, 1; renal injury, 1; scoring system, 1; venom antigenaemia, 1;
and other, 2. Table 1 summarises these primary outcomes, and includes the verbatim data
extraction. The outcomes categorised as ‘other’ included one of antivenom hypersensitivity
reaction [29] and one which was poorly defined [30]. The majority of primary outcome mea-
sures (82�1%) were unique to a single study. Amongst studies with shared primary outcome
Fig 3. UpSet plot summarising methods of snake identification used in snakebite randomised controlled trials. Upper bar chart, x axis: combinations of snake
identification methods; y axis: number of randomised controlled trials using each combination of snake identification methods. Lower left bar chart, x axis: total
numbers of randomised controlled trials using each individual method of snake identification; y axis: individual methods of snake identification.
https://doi.org/10.1371/journal.pntd.0009589.g003
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measures, three by Isbister et al adopted return of INR to less than two [23,24,31] and two
studies measured duration of invasive ventilation [32,33].
For the remainder of the analysis herein, the 153 unique primary and secondary outcome
measures will be considered together. Outcome measures were classified into 60 domains, and
these are detailed in their corresponding categories in Table 2.
Outcome measures in the category ‘coagulopathy’ were included in 72�4% of studies
(n = 42 of 58). An outcome measure in the ‘bedside clotting test’ domain was used in 51�7%
(n = 30) of studies and, within this domain, 18 unique methods of measurement were identi-
fied. These included various iterations of the ‘20-minute whole blood clotting test’, ‘Lee White
clotting time’ and ‘bleeding time’, which were used in 15, 12 and 2 studies, respectively. The
next most widely used coagulation domains were ‘fibrinogen quantification’ (29�3%; n = 17),
and ‘clotting studies’ (24�1%; n = 14).
Outcome measures in the category ‘haemorrhage’ were adopted in 31�0% of studies (n = 18
of 58) and were grouped into the following domains: ‘cessation of local or systemic bleeding’;
‘anaemia’; ‘ISTH defined major bleeding’ and ‘blood transfusion requirement’. The most
widely used was ‘cessation of local or systemic bleeding’ which was adopted in 15�5% of studies
(n = 9) and was measured in four unique ways.
Neurotoxicity outcome measures were reported in 24�1% of studies. Amongst the 14 studies
that used a neurotoxicity outcome measure, the most widely used were ‘ptosis’ (42�9% of stud-
ies); ‘requirement for invasive ventilation’ (42�9% of studies); and ‘duration of invasive ventila-
tion’ (28�6% of studies). ‘Electromyography’ was used in 14�3% and ‘spirometry’ was used in
7�1% of studies with a neurotoxicity outcome measure.
Renal injury outcome measures were adopted in 24�1% of studies (n = 14 of 58) and were
predominantly based on measurements of creatinine or urine output, with various cut-offs for
defining abnormal. 5�2% (n = 3) of studies adopted the RIFLE or KDIGO criteria for defining
Fig 4. Duration of follow-up of outcome measures: grouped by category of envenoming. Fig 4 depicts the time-period of follow-up of outcome measures within
each category. For each outcome measure, the latest time point of follow-up was identified. Time points were grouped as: up to 24 hours; up to 7 days; up to 28 days;
up to 3 months; and over 3 months. Within each category, the proportion of outcome measures with follow-up until each time-point is defined. For example,
mortality outcome measures were always followed up for over 7 days but were never followed up for more than 28 days. No outcome measures were followed up until
between 28 days and 3 months, and therefore this time point is not displayed in Fig 4.
https://doi.org/10.1371/journal.pntd.0009589.g004
PLOS NEGLECTED TROPICAL DISEASES Systematic review of outcome measures in snakebite randomised controlled trials
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0009589 August 2, 2021 20 / 31
Table 2. Overview of outcome categories and domains.











Mortality 18 Mortality 1 18







Extraocular muscle palsy 2 3
Measure of other skeletal
muscle weakness
2 3
















Coagulopathy 42 Bedside clotting test 18 30
- 20-minute whole blood
clotting test
(9) (15)
- Lee White clotting time (6) (12)
- Bleeding time (1) (2)
- Other bedside clotting
assay
(2) (3)
Fibrinogen quantification 5 17
Clotting studies (INR, PT,
APTT)
9 14











Myotoxicity 7 Creatinine kinase 1 6
Myoglobinuria 2 2
Myalgia 1 1






Serum creatinine 2 5
Serum urea 1 3
(Continued)
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Table 2. (Continued)




























Pain—ordinal scale 3 4
Skin and soft tissue
infection
4 4








































Scoring system 1 Snakebite severity score 1 1
Composite
outcome
14 Composite outcome 13 13
Other 19 Duration of hospital
admission
1 16





Hypoxic brain injury 1 1
Leucocyte count 1 1
(Continued)
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acute kidney injury [34,35] including one study where it formed a component of a composite
outcome [36]. The proportion of participants requiring renal replacement therapy were mea-
sured in 10�3% of studies (n = 6); all conducted in India [19,22,34,37–39].
Outcome measures that assessed local tissue damage were adopted in 32�8% of studies
(n = 19 of 58). ‘Development of skin blistering or necrosis’ and ‘swelling measured by circum-
ference of bitten limb’ were the most widely used, being included in 15.5% of studies (n = 9).
The ‘need for amputation, skin grafting or debridement’ outcome domain was only adopted in
one study.
The ‘multipoint scale of physical function’ domain was the most widely adopted measure of
‘functional status’ and included eight functional scales (as reported in S3 Text). All of these
were patient-centred outcomes and were used in three studies; all conducted in the USA
[13,15,40]. A scoring system, the ‘snakebite severity score’ [41], was used in a single study [42].
Composite outcomes were included in 13 studies, and each of these were unique and repre-
sented the primary outcome measures (Table 1).
Adverse event outcome measures
Amongst the trials and protocols (n = 56), there was a failure to record adverse event outcomes
in 32�1% (n = 18) of studies. A total of 69 adverse event outcome measures were extracted ver-
batim, and were grouped as follows: ‘anaphylaxis’, 18; ‘early hypersensitivity reactions’, 6;
‘non-specific early reactions, 19; ‘pyrogenic reactions’, 3; full adverse event reporting (report-
ing of all serious adverse events), 8; ‘transfusion-related acute lung injury’, 2; and ‘serum sick-
ness’, 13. Anaphylaxis was defined based on published criteria in five trials or protocols
[23,24,31,43,44]. Serum sickness was defined based on reproducible clinical criteria in one
published randomised controlled trial, and one trial protocol [42,43].
Discussion
Outcome measures used in clinical trials of snakebite envenoming vary considerably.
Although varied outcome measures are needed to capture the diverse effects of envenoming
Table 2. (Continued)


















Categories were predefined and each represent an established clinical syndrome of envenoming (e.g., neurotoxicity),
or a broad categorisation of the outcome type (e.g., composite outcome). Two reviewers independently categorised
outcome measures and consensus was reached on disagreements.
Domains were defined using a data driven approach. Each domain represents a grouping of outcomes that were
deemed to be measuring a similar parameter. Consensus on domain allocations and domain names was reached by
the primary authors.
APTT = activated partial thromboplastin time, GI = gastrointestinal, ISTH = International Society on Thrombosis
and Haemostasis, INR = international normalised ratio, KDIGO = Kidney Disease: Improving Global Outcomes, and
PT = prothrombin time.
https://doi.org/10.1371/journal.pntd.0009589.t002
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by different species, variations within an outcome domain are undesirable. To achieve the
WHO target of reducing snakebite deaths and disability by 50%, clinical trial outcome mea-
sures must include either direct measures of clinically relevant events or validated surrogate
markers that are known to be associated with risk of disability or death.
This systematic review also demonstrates the troubling landscape of clinical trials in snake-
bite. Many recent trials did not use a sample size calculation, were single centre and were
underpowered. Few clinical trials have been conducted in sub-Saharan Africa or the Middle
East. Policy makers and clinicians are faced with a disturbing lack of data on which to evaluate
antivenoms. Similar to our findings amongst randomised controlled trials of antivenoms, pre-
clinical efficacy testing has used heterogenous methods that in a number of cases prevent com-
parisons between studies [45]. There is an urgent need for standardisation in the way that anti-
venoms are assessed, both pre-clinically and clinically.
Of further concern, many of the included clinical trials used unreliable methods for identi-
fying the biting snake species. As the efficacy of antivenom is often snake species specific,
knowing the biting species is important. Although the majority of trials utilised an assessment
of the morphology of the dead specimen brought to the hospital, this was invariably opportu-
nistic. For those participants who did not attend with the dead specimen, less specific methods
were largely relied upon. Amongst eight of the 43 included clinical trials, participants were
asked to recall and describe the appearance of the snake, and in a further 11 clinical trials no
efforts were made to identify the biting species. The clinical syndrome of envenoming was
used to predict the biting species in 16 clinical trials and, although this method can be reliable
in settings where a single species is the predominant cause of coagulopathy, such as parts of
West Africa, this is not reliable in various other settings. Unfortunately, reliable identification
of the biting species remains challenging, particularly in LMIC settings, and further develop-
ment of enzyme immunoassay and molecular based methods for snake identification are
urgently needed.
There have been just nine randomised controlled trials that have included participants with
neurotoxicity, with a combined sample size of 492 [25–27,32,38,39,46–48]. All except one
study [26] took place in Asia. Many studies adopted measures of eyelid strength or require-
ment for mechanical ventilation. Outcomes used in other neuromuscular disorders may be
useful. For example, the ‘myasthenic muscle score’ is a validated 100-point scale used to assess
therapeutic efficacy in myasthenia gravis [49,50]. A scoring system has the advantage of cap-
turing weakness of various muscle groups and providing a semi-quantitative measure that
may more sensitively detect response to therapeutics. Spirometry, including measurement of
forced vital capacity, offers a potentially sensitive and quantifiable measure of respiratory mus-
cle strength and was used in one included study [25], although its validity in other neuromus-
cular disorders has been disappointing [51]. For phase III clinical trials, pragmatic endpoints
with high clinical relevance will be important, such as the proportion of participants requiring
intubation and ventilation.
Bleeding events were often poorly defined with insufficient detail to allow consistent repli-
cation in future studies [19,52–54]. Bleeding due to snake envenoming tends to involve small
volume blood loss from the bite site, gums, or venepuncture sites. Although the International
Society on Thrombosis and Haemostasis (ISTH) definition [55] of haemorrhage [23,24,31,36],
or laboratory-based measures of anaemia [56–59], provide objective tools, bleeding events of
this severity are rare in snakebite envenoming [60]. Furthermore, measures of haematocrit or
packed cell volume [56–59] may under-estimate anaemia due to the concentration effect of
venom-induced capillary leak syndrome [61].
A range of laboratory assays were used to assess for coagulopathy, and it is uncertain which
is the most useful. The bedside clotting tests do not require any specialist equipment and can
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be conducted in remote rural settings where the majority of snakebites occur. The Lee White
clotting time was used exclusively in studies from South America and Asia [19,37,38,62–67],
whereas the 20-minute whole blood clotting test (20WBCT) has been used more widely
[20,34,47,52–54,56,59,68–71]. Although the 20WBCT has been subject to more frequent vali-
dation than the Lee White clotting time, this has rarely been amongst participants that have
received antivenom [24,72,73] and, therefore, bedside tests of whole blood clotting are inade-
quately validated for measuring response to treatment. A disadvantage of the 20WBCT is that
it is binary rather than continuous. Sensitive continuous outcome measures are desirable for
smaller studies such as phase II clinical trials.
Renal injury can result from envenoming by a range of snake species [74]. Outcome mea-
sures in snakebite clinical trials have focussed on acute renal injury; based on various thresh-
olds of serum creatinine and oliguria. Internationally recognised criteria for the diagnosis of
acute kidney injury are available [75–77], and these were adopted in three of the included stud-
ies [34,35], including within one composite outcome [36]. Although the need for renal replace-
ment therapy (RRT) is an important measure, there is wide variation and no consensus on the
optimal timing for initiating and stopping this in acute kidney injury [78]. Follow-up studies
of adults and children with snake venom induced renal injury have demonstrated a 30% risk
of progression to chronic kidney disease [79,80]. Chronic kidney disease is defined as an
abnormality in the structure or functioning of the kidneys present for a minimum of 3 months
[81]. No outcome measures fulfilled this definition and the need for longer follow-up of renal
function in clinical trials should be considered.
Snakebite associated local tissue damage represents a varied spectrum of disease, ranging
from swelling to necrosis, with complications including infection, contractures, and amputa-
tion. Although this range of disease was captured across the extracted outcomes, this was
inconsistent between studies. Consensus on a list of outcomes, including details of how they
should be measured, is needed. For example, limb swelling has been measured by circumfer-
ence [18,27,35,47,63], distance of proximal extension [40,58,59], or limb volume [40,82].
Complications of local tissue damage can cause loss of physical function with a varying
impact depending on an individual’s circumstances. Many people with snakebite are vulnera-
ble and disability may significantly impact on their ability to work, subsistence farm or care for
children. Patient-centred outcomes are key for capturing this, but such outcomes were only
adopted in trials based in the USA [13,15,40]. The patient specific functional scale (PSFS) is
simple (although does require numeracy) and allows patients to identify functions that are
important to them. This tool has been validated for snakebite envenoming [13], although not
in an LMIC setting.
Adverse event reporting varied significantly between the randomised controlled trials, and
32�1% of the included studies failed to report adverse events. As antivenom is an animal
derived product, there is a significant risk of life-threatening anaphylaxis, yet only five of the
56 included studies used standardised published criteria for defining anaphylaxis. Given that
the risk of anaphylaxis can vary substantially between antivenom products [7,83], it is essential
that the rate of occurrence of these events can be reliably and consistently measured in clinical
trials. Serum sickness was only reported as an outcome measure in 13 of the 58 included stud-
ies, and only two studies used clearly defined clinical criteria [42,43]. A standardised definition
of anaphylaxis and serum sickness should be included in a core outcome set.
Limitations
When considering outcome measures for use in a core outcome set, it is important to ascertain
whether they are valid, reliable, and feasible. Such an assessment was outside the scope of this
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study and will form the next stage of COS development. This systematic review did not restrict
on the age or quality of the trials; however, this was important to ensure all outcome measures
were captured. When describing the characteristics and quality of trials, data for studies pub-
lished more recently were presented. At this stage there has not been any patient involvement
and future work on COS development will strive to involve people who have directly experi-
enced snakebite.
Conclusions
This study has identified significant heterogeneity of outcome measures in snakebite clinical
trials. There is a strong need for a core outcome set, which will support the adoption of valid,
reproducible, and patient-centred outcome measures, and enable downstream meta-analyses.
Validated outcome measures are particularly important when assessing antivenom efficacy, as
this expensive therapy is associated with a relatively high risk of adverse events. To provide
global relevance that can span the diversity of snake species, outcomes that represent each of
the syndromes of envenoming are needed. Through better outcome measures, together with
increased global recognition of the importance of snakebite envenoming, high quality clinical
trials in populations with the greatest burden of disease can be achieved.
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